{"url_path":"/sec/atnm/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1388320/0001213900-26-053980-index.html","accession_number":"0001213900-26-053980","cik":"0001388320","ticker":"ATNM","issuer_name":"Actinium Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1388320/0001213900-26-053980-index.html","primary_entity_key":"0001388320","primary_entity_name":"Actinium Pharmaceuticals, Inc."},"word_count":683,"has_tables":true,"body_markdown":"**ITEM 6. EXHIBITS**\n\n \n\nCopies of the following documents\nare included as exhibits to this report pursuant to Item 601 of Regulation S-K.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n3.1\n \n[Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on April 17, 2013).](http://www.sec.gov/Archives/edgar/data/1388320/000121390013001911/f8k041113ex3i_actinium.htm)\n\n \n \n \n\n3.2\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014).](http://www.sec.gov/Archives/edgar/data/1388320/000121390014000604/fs12014ex3v_actinium.htm)\n\n \n \n \n\n3.3\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014).](http://www.sec.gov/Archives/edgar/data/1388320/000121390014000688/f8k020314ex3i_actinium.htm)\n\n \n \n \n\n3.4\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015).](http://www.sec.gov/Archives/edgar/data/1388320/000121390015001553/f8k022615ex3i_actinium.htm)\n\n \n \n \n\n3.5\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018).](http://www.sec.gov/Archives/edgar/data/1388320/000121390018002270/f8k022618ex3-1_actinium.htm)\n\n \n \n \n\n3.6\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019).](http://www.sec.gov/Archives/edgar/data/1388320/000121390019004269/f10k2018ex3-7_actinium.htm)\n\n \n \n \n\n3.7\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).](http://www.sec.gov/Archives/edgar/data/1388320/000121390020015104/ea123121ex3-1_actiniumpharma.htm)\n\n \n \n \n\n3.8\n \n[Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020).](http://www.sec.gov/Archives/edgar/data/1388320/000121390020022322/ea125571ex3-1_actinium.htm)\n\n \n \n \n\n3.9\n \n[Amended and Restated Bylaws, dated August 9, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018).](http://www.sec.gov/Archives/edgar/data/1388320/000121390018010603/f10q0618ex3-1_actinium.htm)\n\n \n \n \n\n3.10\n \n[Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020).](http://www.sec.gov/Archives/edgar/data/1388320/000121390020011052/ea121342ex3-1_actinium.htm)\n\n \n \n \n\n31.1*\n \n[Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea028646701ex31-1.htm)\n\n \n \n \n\n32.1**\n \n[Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea028646701ex32-1.htm)\n\n \n \n \n\n101.INS*\n \nInline XBRL Instance Document\n\n101.SCH*\n \nInline XBRL Taxonomy Schema Document\n\n101.CAL*\n \nInline XBRL Taxonomy Calculation Linkbase Document\n\n101.DEF*\n \nInline XBRL Taxonomy Definition Linkbase Document\n\n101.LAB*\n \nInline XBRL Taxonomy Label Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Presentation Linkbase Document\n\n104*\n \nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n*\nFiled herewith.\n\n \n\n**\nFurnished herewith.\n\n \n\n78\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto\nduly authorized.\n\n \n\n \n**ACTINIUM PHARMACEUTICALS, INC.**\n\n \n \n \n\nDate: May 8, 2026\nBy: \n*/s/ Sandesh Seth*\n\n \n \nSandesh Seth\n\n \n \nChairman and Chief Executive Officer\n\n(Duly Authorized Officer, Principal Executive Officer, Principal Financial Officer)\n\n \n\n79\n\n0001388320\nfalse\nQ1\n--12-31\n\n0001388320\n\n2026-01-01\n2026-03-31\n\n0001388320\n\n2026-05-07\n\n0001388320\n\n2026-03-31\n\n0001388320\n\n2025-12-31\n\n0001388320\n\natnm:RevenueMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\natnm:RevenueMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\natnm:OtherRevenueMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\natnm:OtherRevenueMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001388320\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001388320\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-12-31\n\n0001388320\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001388320\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001388320\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-03-31\n\n0001388320\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001388320\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001388320\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-12-31\n\n0001388320\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001388320\n\n2024-12-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001388320\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001388320\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-03-31\n\n0001388320\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001388320\n\n2025-03-31\n\n0001388320\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\n2012-06-15\n2012-06-15\n\n0001388320\n\nsrt:MinimumMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nsrt:MaximumMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nsrt:MaximumMember\n\n2026-03-31\n\n0001388320\n\nsrt:MinimumMember\n\n2026-03-31\n\n0001388320\n\natnm:OperatingLeasesMember\n\n2025-12-31\n\n0001388320\n\natnm:FinanceLeasesMember\n\n2025-12-31\n\n0001388320\n\n2022-04-07\n2022-04-07\n\n0001388320\n\natnm:CapitalOnDemandSalesAgreementMember\n\n2020-08-01\n2020-08-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2023-08-11\n2023-08-11\n\n0001388320\n\nsrt:MinimumMember\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001388320\n\nus-gaap:CommonStockMember\n\n2025-03-01\n2025-03-31\n\n0001388320\n\nus-gaap:StockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001388320\n\nus-gaap:StockOptionMember\n\n2026-03-31\n\n0001388320\n\nus-gaap:StockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001388320\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001388320\n\nus-gaap:WarrantMember\n\n2026-03-31\n\nxbrli:shares\n\niso4217:USD\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure"}